Simcere Pharmaceutical Group (STU:S2P) Total Operating Expense: €594.9 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:S2P Simcere Pharmaceutical Group Ltd STU:S2P
94 GF Score
Price €1.38
GF Value €1.16
View Full Analysis

What is Simcere Pharmaceutical Group Total Operating Expense?

Simcere Pharmaceutical Group STU:S2P -2.82% 94 Total Operating Expense is €594.9 Mil as of Dec. 2025. GuruFocus rates STU:S2P with a GF Score™ of 94/100 and a GF Value™ of €1.16.

Simcere Pharmaceutical Group's Total Operating Expense for the six months ended in Dec. 2025 was €331.0 Mil. Simcere Pharmaceutical Group's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was €594.9 Mil.

Simcere Pharmaceutical Group Total Operating Expense Related Terms

Simcere Pharmaceutical Group Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Simcere Pharmaceutical Group's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Simcere Pharmaceutical Group Total Operating Expense Chart

Simcere Pharmaceutical Group Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only 517.42 602.81 550.27 555.09 596.00

Simcere Pharmaceutical Group Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 265.03 241.79 307.42 263.87 331.02
STU:S2P
94GF Score
Simcere Pharmaceutical Group Ltd STU:S2P
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Simcere Pharmaceutical Group Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €594.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €594.9 Mil mean?
Simcere Pharmaceutical Group (STU:S2P) has a Total Operating Expense of €594.9 Mil as of Dec. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on Simcere Pharmaceutical Group and its competitors.
Is Simcere Pharmaceutical Group's Total Operating Expense too high?
Simcere Pharmaceutical Group's current Total Operating Expense is €594.9 Mil. Overall, Simcere Pharmaceutical Group has a GF Score™ of 94/100, reflecting its overall financial health beyond just this single metric.
How does Simcere Pharmaceutical Group's Total Operating Expense compare to ZTS and UTHR?
Simcere Pharmaceutical Group's Total Operating Expense of €594.9 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Drug Manufacturers company?
A good Total Operating Expense depends on the Drug Manufacturers industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Simcere Pharmaceutical Group and its competitors. Simcere Pharmaceutical Group's current Total Operating Expense is €594.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Simcere Pharmaceutical Group stock overvalued right now?
Simcere Pharmaceutical Group (STU:S2P) has a current Total Operating Expense of €594.9 Mil. The stock's GF Value™ is €1.16, compared to a current price of €1.38 — trading 19% above its estimated fair value. The current Total Operating Expense is €594.9 Mil. Simcere Pharmaceutical Group's overall GF Score™ is 94/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Simcere Pharmaceutical Group (STU:S2P), the current Total Operating Expense is €594.9 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Simcere Pharmaceutical Group (STU:S2P) Overvalued in 2026?

Based on GuruFocus' analysis, Simcere Pharmaceutical Group stock appears to be overvalued. The current stock price of €1.38 is trading 19% above its estimated GF Value™ of €1.16.

Key valuation signals for STU:S2P:

  • Total Operating Expense: €594.9 Mil
  • GF Value™: €1.16 vs. price of €1.38 (19% above fair value)
  • GF Score™: 94/100

No single metric tells the full story. See the STU:S2P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Simcere Pharmaceutical Group Business Description

Other Exchanges 02096:Hong Kong
Address No. 699-18, Xuanwu Road, Xuanwu District, Jiangsu Province, Nanjing, CHN, 210042
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production, and commercialization of pharmaceuticals focused on generic pharmaceuticals. The company has a diversified product portfolio focused on therapeutic areas, including, neuroscience, anti-oncology, autoimmune, and antiinfection. The company's products include Endostar, Enweida, Enzeshu, Iremod, Quviviq, Cosela, Sanbexin and Others.
94GF Score

Get the complete analysis for STU:S2P

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.38
Price
€1.16
GF Value